We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.
- Authors
Liu, H-l; Sun, Z-m; Geng, L-q; Wang, X-b; Ding, K-y; Tong, J; Tang, B-l; Zhou, C-y; Yao, W; Zheng, C-c; Song, K-d; Zhu, X-y; Wei, W; Wang, Y
- Abstract
This study included data from 185 consecutively treated patients, 16 years of age or older, who underwent myeloablative transplantation using unrelated umbilical cord blood (UCB) (UCB transplantation (UCBT), n=70) or HLA-identical sibling donor peripheral blood stem cells alone or combined with bone marrow (BMT/PBSCT, n=115) from October 2001 to December 2012. All patients received myeloablative regimens, cyclosporin A plus mycophenolate mofetil as prophylaxis for GVHD, and similar supportive care. Although hematopoietic recovery was significantly delayed after UCBT, the rate of neutrophil engraftment was comparable. The median follow-up was 53 months (range, 15-136 months) for BMT/peripheral blood SCT (PBSCT) recipients and 35 months (range, 10-123 months) for UCBT recipients. There were no significant differences in the cumulative incidence of grades III to IV acute GVHD, relapse rate, or 3-year probabilities of disease-free survival between patients receiving UCBT and those receiving BMT/PBSCT. However, the cumulative incidence of chronic and extensive chronic GVHD was lower in UCBT recipients. The rates of long-term survivors returning to school or work and off immunosuppressive therapy were significantly higher after UCBT, which indicated that long-term survivors who underwent UCBT had a higher quality of life.
- Subjects
QUALITY of life; CORD blood transplantation; BONE marrow; CYCLOSPORINE; MYCOPHENOLIC acid; ORGAN donors; STEM cells
- Publication
Bone Marrow Transplantation, 2014, Vol 49, Issue 8, p1063
- ISSN
0268-3369
- Publication type
Article
- DOI
10.1038/bmt.2014.102